



Name : Dr. Yogeshwar Bachhav

Designation : Associate Director (Pharmaceutical Development), Consultant at
AiCuris Anti-infective Cures AG, Germany

Qualification : M. Pharm.Sci, Ph. D (Tech)

Specialization : Pharmaceutics

Email id : yogeshudct@gmail.com

Phone : +91-9004534236

Experience : 16 years

Industry experience:

1. Associate Director (Consultant) Associate Director (Consultant)
AiCuris Anti-infective Cures AG · Mar 2014 - Present (8 Yrs 6 Months)
2. Formulation Development Manager Formulation Development Manager
Debiopharm International, Lausanne, Switzerland
Jul 2010 - Feb 2014 · 3 Yrs 8 Moths
3. Research Scientist
Pantec BioSolutions AG, Geneva Switzerland
Mar 2007 - Jun 2010 · 3 Yrs 4 Moths
4. Research Associate
Sun Pharmaceutical Industries Advanced Research Center, Mumbai, India
Jul 2003 - Dec 2003 · 6 Moths

Areas of interest

- Drug substance and drug product manufacturing for clinical trials
- Design and implementation of strategies for Preformulation and formulation development for preclinical and clinical trials and life cycle management
- Outsourcing formulation development activities with CROs and CMOs
- CMC Project Management
- Clinical trial supply
- Business Intelligence

Research

- ✓ https://pubmed.ncbi.nlm.nih.gov/?term=Bachhav+YG&cauthor_id=20678988
- ✓ https://de.linkedin.com/in/yogeshwar-bachhav-10738a13?original_referer=https%3A%2F%2Fwww.google.com%2F
- ✓ <https://patents.google.com/?inventor=Yogeshwar+BACHHAV>
- Publications: 16
- Edited 02 Books for Wiley-VCH Germany
- Book Chapters: 01
- Patents: 06 (International)
- Presentations: International presentations
- Invited international talks 06
- Founder and Director of Adex Pharma Consultancy Services

Completed: Several industry-sponsored projects with a budget of total around 50 -60 lakhs

Academic activities

- He has worked as co-guided 06 M. Pharm students (Pharmaceutical Sciences) at the University of Geneva, Switzerland

Awards & Achievements

- for Technical Education (AICTE), New Delhi, India for M.Pharm., 2007 – 2009.
- Received Junior Research Fellowship from University Grants Commission (2001-2003)
- Received Senior Research Fellowship from University Grants Commission (2004-2007)
- Qualified GATE – Pharmacy 2001, with 99.70 percentile (AIR 11)

Professional Memberships

- Controlled Release Society, USA
- American Association of Pharmaceutical Scientists
- Serving Treasurer of Controlled Release Society, Indian Chapter

Recent Publications

1. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34⁺ Stem/Progenitor Cells. *Mol Cancer Ther.* 2017 Aug;16(8):1497-1510
2. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. *Mol Cancer Ther.* 2016 Oct;15(10):2334-2343
3. Controlled intra- and transdermal protein delivery using a minimally invasive Erbium: YAG fractional laser ablation technology. *Eur J Pharm Biopharm.* 2013 Jun;84(2):355-64
4. Using controlled laser-microporation to increase transdermal delivery of prednisone. *J Control Release.* 2010 Nov 20;148(1):e71-3
5. Using laser microporation to improve transdermal delivery of diclofenac: Increasing bioavailability and the range of therapeutic applications. *Eur J Pharm Biopharm.* 2011 Aug;78(3):408-14.
6. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. *J Control Release.* 2011 Jul 30;153(2):126-32.
7. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation. **Bachhav YG, Patravale VB.**

8. Development and validation of a rapid high-performance liquid chromatography method for the quantification of exenatide. *Biomed Chromatogr.* 2011 Jul;25(7):838-42.
9. Effect of controlled laser microporation on drug transport kinetics into and across the skin. *J Control Release.* 2010 Aug 17;146(1):31-6.
10. Development and validation of an analytical method for the quantification of cytochrome c in skin transport studies. *Biomed Chromatogr.* 2010 Jul;24(7):732-6.
11. Stability of triptorelin in the presence of dermis and epidermis. *Int J Pharm.* 2009 Aug 13;378(1-2):149-51.
12. Microemulsion-based vaginal gel of clotrimazole: formulation, in vitro evaluation, and stability studies. *AAPS PharmSciTech.* 2009;10(2):476-81
13. SMEDDS of glyburide: formulation, in vitro evaluation, and stability studies. *AAPS PharmSciTech.* 2009;10(2):482-7. The microemulsion-based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation. *Int J Pharm.* 2009 Jan 5;365(1-2):175-9.
14. Intraepidermal drug delivery: P.L.E.A.S.E.® - A new laser microporation technology. *Drug Delivery Technology,* 2008; 8: 26-31.
15. Exploring the potential of N-methyl pyrrolidone as a cosurfactant in the microemulsion systems. *Int J Pharm.* 2006 Dec 1;326(1-2):186-9